A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

被引：0
|
作者：
J. P. Arnoletti
A. Frolov
M. Eloubeidi
K. Keene
J. Posey
T. Wood
Edward Greeno
N. Jhala
S. Varadarajulu
S. Russo
J. Christein
R. Oster
D. J. Buchsbaum
S. M. Vickers
机构：
[1] University of Alabama at Birmingham,Department of Surgery
[2] University of Alabama at Birmingham,Department of Gastroenterology
[3] University of Alabama at Birmingham,Department of Radiation Oncology
[4] University of Alabama at Birmingham,Department of Medical Oncology
[5] University of Minnesota,Division of Hematology, Oncology and Transplantation
[6] University of Alabama at Birmingham,Department of Pathology
[7] East Carolina University,Department of Radiation Oncology
[8] University of Alabama at Birmingham,Department of Biostatistics
[9] University of Minnesota, Surgery Department
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cetuximab; Gemcitabine; Radiation therapy; Pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：891 / 897
页数：6
相关论文
共 50 条
  • [21] Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)
    Xiong, Feng
    Zhou, Yu-Wen
    Hao, Ya-Ting
    Wei, Gui-Xia
    Chen, Xiao-Rong
    Qiu, Meng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (4-5) : 185 - 192
  • [22] Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies
    Guarino, Michael J.
    Schneider, Charles J.
    Hosford, Martha A.
    Brahmer, Julie R.
    Rudin, Charles M.
    Finckenstein, Friedrich Graf
    Philip-Norton, Robyn E.
    Lu, Haolan
    Weber, Martin R.
    Ettinger, David S.
    ONCOLOGIST, 2009, 14 (02) : 119 - 124
  • [23] Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates
    Tikum, Anjong Florence
    Nambisan, Anand Krishnan
    Ketchemen, Jessica Pougoue
    Babeker, Hanan
    Khan, Musharraf N.
    Torlakovic, Emina E.
    Fonge, Humphrey
    PHARMACEUTICS, 2022, 14 (09)
  • [24] Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: Another one or the one?
    Messersmith, Wells A.
    Hidalgo, Manuel
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4664 - 4666
  • [25] Randomized phase II – study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer – PARC: study protocol [ISRCTN56652283]
    R Krempien
    MW Muenter
    PE Huber
    S Nill
    H Friess
    C Timke
    B Didinger
    P Buechler
    S Heeger
    KK Herfarth
    A Abdollahi
    MW Buchler
    J Debus
    BMC Cancer, 5
  • [26] Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Ferrara, Marianna Luciana
    Rossi, Antonio
    ONCOLOGIST, 2009, 14 (06) : 601 - 611
  • [27] Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
    Montagut, C.
    Iglesias, M.
    Arumi, M.
    Bellosillo, B.
    Gallen, M.
    Martinez-Fernandez, A.
    Martinez-Aviles, L.
    Canadas, I.
    Dalmases, A.
    Moragon, E.
    Lema, L.
    Serrano, S.
    Rovira, A.
    Rojo, F.
    Bellmunt, J.
    Albanell, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (07) : 1137 - 1144
  • [28] Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
    C Montagut
    M Iglesias
    M Arumi
    B Bellosillo
    M Gallen
    A Martinez-Fernandez
    L Martinez-Aviles
    I Cañadas
    A Dalmases
    E Moragon
    L Lema
    S Serrano
    A Rovira
    F Rojo
    J Bellmunt
    J Albanell
    British Journal of Cancer, 2010, 102 : 1137 - 1144
  • [29] Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
    U Graeven
    B Kremer
    Th Südhoff
    B Killing
    F Rojo
    D Weber
    J Tillner
    C Ünal
    W Schmiegel
    British Journal of Cancer, 2006, 94 : 1293 - 1299
  • [30] Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
    Graeven, U
    Kremer, B
    Südhoff, T
    Killing, B
    Rojo, F
    Weber, D
    Tillner, J
    Ünal, C
    Schmiegel, W
    BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1293 - 1299
12345